Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30818693 | 1.00 | GAA (0.51) | GAAHTTPOLBCNR2SMN1; SMN2 | |
| SCHEMBL6843345 | 0.86 | GAA (0.59) | GAAHTTPOLBSMN1; SMN2PIK3CA | |
| Phenylboronic Acid SCHEMBL3453507 | 0.85 | GAA (0.44) | GAAHTTPOLBCNR2SMN1; SMN2 | |
| SCHEMBL14897578 | 0.82 | ALOX5 (0.46) | SMN1; SMN2MAPTTSHRDRD2DRD3 | |
| SCHEMBL14896676 | 0.82 | ALOX5 (0.46) | GAASMN1; SMN2MAPTDRD2DRD3 | |
| SCHEMBL31195791 | 0.81 | HSD17B14 (0.47) | GAAPOLBSMN1; SMN2MAPTTSHR | |
| SCHEMBL22334883 | 0.79 | GAA (0.53) | GAAHTTPOLBSMN1; SMN2PIK3CA | |
| SCHEMBL4945956 | 0.78 | GAA (0.59) | GAAHTTPOLBCNR2SMN1; SMN2 | |
| SCHEMBL17787692 | 0.78 | GAA (0.51) | GAAHTTPOLBSMN1; SMN2PIK3CA | |
| SCHEMBL12654053 | 0.78 | HTR3E (0.64) | GAAHTTPOLBSMN1; SMN2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109119-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4469436-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | Evvia Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147312-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | EVVIA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2768834-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-9012446-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2013059587-A9 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2014-02-13 | — | — | US | disclosed |
| EP-2547686-B1 | AMINO-DIHYDROOXAZINE AND AMINO-DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA-SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8497264-B2 | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| WO-2013059589-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059594-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-2547686-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115928-A1 | AMINO -DIHYDROOXAZINE AND AMINO - DIHYDROTHIAZINE SPIRO COMPOUNDS AS BETA - SECRETASE MODULATORS AND THEIR MEDICAL USE | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045828-A1 | AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, APP, BACE2 | GAA 633/4885HTT 3502/4885POLB 3117/4885 |
| US-20110251186-A1 | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, APP, BACE2 | GAA 633/4885HTT 3502/4885POLB 3117/4885 |
| US-20250109119-A1 | AMPK AGONISTS AND METHODS OF USE THEREOF | PRKAG3, PRKAG1, PRKAG2 | GAA 628/4885HTT 2260/4885POLB 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.